SCHEMBL5717751

SCHEMBL5717751

NC(=O)CNC(=O)c1cccs1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.64
▸ TSHR P16473 2/20 0.58
▸ HDAC1 Q13547 1/20 0.58
▸ NPC1 O15118 9/20 0.57
▸ RAB9A P51151 8/20 0.57
▸ SMN1; SMN2 Q16637 4/20 0.57
▸ GAA P10253 1/20 0.54
▸ MEN1 O00255 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ HPGD P15428 2/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ HTT P42858 1/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ MAPT P10636 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1222245 0.84 KDM4E (0.66) KDM4ETSHRHDAC1NPC1RAB9A
SCHEMBL7394648 0.84 KDM4E (0.66) KDM4ETSHRHDAC1NPC1RAB9A
SCHEMBL7503385 0.83 KDM4E (0.70) KDM4ETSHRHDAC1NPC1RAB9A
SCHEMBL5855304 0.82 KDM4E (0.64) KDM4ETSHRHDAC1NPC1RAB9A
SCHEMBL5856266 0.81 KDM4E (0.62) KDM4ETSHRHDAC1NPC1RAB9A
SCHEMBL15247363 0.79 KDM4E (0.60) KDM4ETSHRHDAC1NPC1RAB9A
SCHEMBL5857396 0.79 TSHR (0.64) KDM4ETSHRHDAC1NPC1RAB9A
SCHEMBL21479628 0.79 KDM4E (0.60) KDM4ETSHRHDAC1NPC1RAB9A
SCHEMBL26333913 0.79 KDM4E (0.60) KDM4ETSHRHDAC1NPC1RAB9A
SCHEMBL355263 0.79 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013144737-A2 NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2013-10-03 — — WO disclosed
EP-1363925-B1 MACROLIDE ANTIBIOTICS GLAXO GROUP LTD (GB) 2006-11-15 — — EP disclosed
US-20060211636-A1 Macrolide Antibiotics ALIHODZIC SULEJMAN 2006-09-21 — — US disclosed
US-20050215495-A1 Macrolide antibiotics ALIHODZIC SULEJMAN 2005-09-29 — — US disclosed
US-20040077557-A1 Macrolide antibiotics GLAXO GROUP LIMITED (GB) 2004-04-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215495-A1 Macrolide antibiotics IL1R1, MRPL12, RPS21 KDM4E 1204/4885TSHR 723/4885HDAC1 226/4885
US-20060211636-A1 Macrolide Antibiotics IL1R1, MRPL12, RPS21 KDM4E 1204/4885TSHR 723/4885HDAC1 226/4885
US-20040077557-A1 Macrolide antibiotics MALT1, MRPL21, IL1R1 KDM4E 1358/4885TSHR 1579/4885HDAC1 193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback